Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (261-270 of 303) with videos related to

Pageof 31
Sort By:
International Journal of Radiation Oncology, Biology, Physics|February 12, 2022
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 TherapyKyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, et al.
JCO Precision Oncology|July 23, 2025
Deep-Learning Model for Real-Time Prediction of Recurrence in Early-Stage Non-Small Cell Lung Cancer: A Multimodal Approach (RADAR CARE Study)Hyun Ae Jung, Daehwan Lee, Boram Park, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.
Cancer Research and Treatment|May 2, 2024
Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 TrialJunghoon Shin, Sehhoon Park, Kyung Hwan Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|July 27, 2022
Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung CancerKyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, et al.
Oncotarget|January 13, 2016
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Ji Yun Lee, Xu Qing, Wei Xiumin, et al.
Cancer|June 8, 2012
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trialJong-Mu Sun, Ki Hyeong Lee, Sang-We Kim, et al.
The Journal of Molecular Diagnostics : JMD|December 19, 2012
Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancerMaruja E Lira, Tae Min Kim, Donghui Huang, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 26, 2021
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer modelJiae Koh, Sohyun Kim, Sang Nam Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)Sehhoon Park, Richard Baldry, Hyun Ae Jung, et al.
Pageof 31

Showing results (261-270 of 303) with videos related to

Sort By:
Pageof 31
International Journal of Radiation Oncology, Biology, Physics|February 12, 2022
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 TherapyKyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, et al.
JCO Precision Oncology|July 23, 2025
Deep-Learning Model for Real-Time Prediction of Recurrence in Early-Stage Non-Small Cell Lung Cancer: A Multimodal Approach (RADAR CARE Study)Hyun Ae Jung, Daehwan Lee, Boram Park, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.
Cancer Research and Treatment|May 2, 2024
Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 TrialJunghoon Shin, Sehhoon Park, Kyung Hwan Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|July 27, 2022
Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung CancerKyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, et al.
Oncotarget|January 13, 2016
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Ji Yun Lee, Xu Qing, Wei Xiumin, et al.
Cancer|June 8, 2012
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trialJong-Mu Sun, Ki Hyeong Lee, Sang-We Kim, et al.
The Journal of Molecular Diagnostics : JMD|December 19, 2012
Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancerMaruja E Lira, Tae Min Kim, Donghui Huang, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 26, 2021
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer modelJiae Koh, Sohyun Kim, Sang Nam Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)Sehhoon Park, Richard Baldry, Hyun Ae Jung, et al.
Pageof 31